EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Rapport Therapeutics's Enterprise Value is $53.13 Mil.
Rapport Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $-67.23 Mil. Therefore, Rapport Therapeutics's EV-to-FCF for today is -0.79.
The historical rank and industry rank for Rapport Therapeutics's EV-to-FCF or its related term are showing as below:
RAPP'
s EV-to-FCF Range Over the Past 10 Years
Min: -41.96 Med: 0 Max: 0.89
Current: -0.79
During the past 3 years, the highest EV-to-FCF of Rapport Therapeutics was 0.89. The lowest was -41.96. And the median was 0.00.
RAPP's EV-to-FCF is ranked worse than 100% of 420
companies
in the Biotechnology industry
Industry Median: 3.74
vs RAPP: -0.79
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Rapport Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Rapport Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Rapport Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapport Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rapport Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Rapport Therapeutics's EV-to-FCF falls into.
Rapport Therapeutics's current Enterprise Value is $53.13 Mil.
Rapport Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-67.23 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapport Therapeutics (NAS:RAPP) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rapport Therapeutics's PE Ratio (TTM) for today is calculated as:
Rapport Therapeutics's share price for today is $10.12.
Rapport Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.710.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Rapport Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Rapport Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RAPP has been successfully added to your